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Background: To determine appropriate timing of an adaptive radiation therapy (ART) replan by evaluating anatomic
and dosimetric changes of target volumes and organs at risk (OARs) during intensity-modulated radiation therapy (IMRT)
for nasopharyngeal carcinoma (NPC).
Methods: Nineteen NPC patients were recruited. Each patient had repeat computed tomography (CT) scans after each
five fractions and at treatment completion. Automatic re-contouring the targets and OARs by using deformable
registration algorithm was conducted through CT-CT fusion. Anatomic changes were assessed by comparing the initial
CT and repeated CT. Hybrid plans with re-contouring were generated and the dose-volume histograms (DVH) of the
hybrid plan and the original plan were compared.
Results: Progressive volume reductions in gross target volume for primary disease (GTVnx), gross target volume for
involved lymph nodes (GTVnd), and parotids were observed over time. Comparing with the original plan, each hybrid
plan had no significant difference in homogeneity index (HI) for all the targets. Some parameters for planning target
volumes for primary disease and high-risk clinical target volume (PTVnx and PTV1, respectively) improved significantly,
notably starting from the 10th fraction. These parameters included mean dose (Dmean), dose to 95 % of the volume
(D95), percentage of the volume receiving 95 % of the prescription dose (V95), and conformity index (CI) for PTVnx, and
Dmean, D95, and CI for PTV1. The dosimetric parameters for PTVnd remained the same in general except for D95 and
V95 which had significant improvement at specific time points; whereas for PTV2, similar trend of dosimetric changes
was also observed. Dose to some OARs increased significantly at some time points.
Conclusions: There were significant anatomic and dosimetric changes in the targets and OARs. The target dose
coverage in the hybrid plans did not get worse, but overdose occurred in some critical structures. Significant dosimetric
changes should be considered as a trigger point at which ART replanning is indicated. D95/V95/CI for PTV2, Dmax for
the brain stem, spinal cord, right eyeball and left lens, and Dmean/V30 for the parotids and glottis were taken into
account for predicting the need for ART. Two replans at the 5th and 15th fractions were suggested.Background
Radiation therapy (RT) is considered a main treatment ap-
proach in the management of nasopharyngeal carcinoma
(NPC). Intensity-modulated radiation therapy (IMRT),
formally introduced in clinical practice since early 1990s,
has now replaced conventional radiation therapy (CRT)
and three-dimensional radiation therapy (3D-CRT) and* Correspondence: luhming3632@163.com
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provides adequate target coverage while maintaining steep
dose gradients at the border between the target and adja-
cent normal tissues, through which dose escalation for the
targets may be achieved without delivering excessive dose
to the organs at risk (OARs) [1]. Numerous studies have
demonstrated that IMRT results in a decreased incidence
of radiation-induced side effects and an improvement in
quality of life (QOL) for NPC patients, comparing with
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tomical changes throughout the entire treatment course.
These changes include the shrinkage of the primary dis-
ease and metastatic lymph nodes, external contour be-
cause of significant weight loss, and displacement/size of
the normal structures. As a consequence of the anatomic
changes, significant difference between the actual deliv-
ered dose and the initial planned dose would be antici-
pated, which may ultimately result in underdose to the
targets and/or overdose to the critical structures. Wang
et al. [7] compared a repeated CT after treatment at a dose
of 40 Gy with the initial planning CT for 20 patients with
locally advanced NPC, and found that the dose coverage
of the targets remained unchanged; whereas the dose de-
livered to the parotid glands and spinal cord increased sig-
nificantly. Excessive irradiation to OARs increased the risk
of incidence of radiation-induced complications such as
xerostomia and myelitis, which may have a great negative
impact on QOL [8–12].
It is suggested that the initial planning based on pre-
treatment condition may not truly reflect the dosimetric
variations during the course of IMRT. Thus adaptive radi-
ation therapy (ART), a plan modification and implementa-
tion according to tumor response and anatomic changes
of normal structures, becomes particularly important. In
recent years, many studies have focused on ART for NPC
patients, however, the optimal timing and frequency of
ART remains unanswered [13–19]. In this prospective
study, we aimed to determine appropriate timing to per-
form an ART replan by evaluating anatomic and dosimet-




Patients with histologically proven NPC and treated with
curative IMRT were enrolled into this prospective study.
Inclusion criteria were as follows: age ≥18 years; Eastern
Cooperative Oncology Group (ECOG) Performance Sta-
tus 0–2; stages I-IVb according to the 2010 AJCC Staging
System. Patients diagnosed with, or treated for other ma-
lignances, or treated with non-IMRT techniques were ex-
cluded in the study. Written informed consent was
obtained for all patients. The study was approved by the
Institutional Review Board (IRB) .
Immobilization and simulation
All patients were immobilized in a supine position with
the head in a neutral position with a tailored thermoplas-
tic mask covering the head, neck, and shoulders. Intraven-
ous contrast-enhanced CT using 2 mm slice from the
vertex to the manubriosternal joint was performed for
planning. The CT data were imported to the a treatment
planning system (Pinnacle3, version 9.2).Delineation of the targets and OARs
The target delineation was in accordance with the Inter-
national Commission on Radiation Units and Measure-
ments Reports 50 and 62. Briefly, the primary gross
volume (GTVnx) and the involved cervical lymphadenop-
athy (GTVnd) included all known gross disease as deter-
mined by the imaging, clinical, and endoscopic findings.
The high-risk clinical target volume (CTV1) was defined
as GTVnx plus 5-mm margin and entire nasopharyngeal
mucosa plus 5-mm submucosal volume. The low-risk clin-
ical target volume (CTV2) covered CTV1, entire naso-
pharynx, parapharyngeal space, pterygopalatine fossa,
posterior third of the nasal cavity and maxillary sinuses, in-
ferior sphenoid sinus, posterior ethmoid sinus, skull base,
and anterior half of the clivus. CTV2 also covered elective
neck nodal regions, including bilateral retropharyngeal
lymph nodes and ipsilateral levels II, III, and Va for node-
negative neck, or full length of ipsilateral neck for node-
positive neck. Level Ib was not routinely irradiated unless
there was confirmed lymphadenopathy in level Ib, or large
metastatic node size (≥3 cm)/extracapsular spread was
present in level IIa. PTVnx, PTVnd, PTV1, and PTV2
were generated by adding 5-mm margin to GTVnx,
GTVnd, CTV1, and CTV2, respectively. Care was taken to
ensure at least 5-mm gap was present between the PTVs
and the skin. The contoured critical structures included
the brain stem, chiasm, optic nerves, spinal cord, eyes,
lens, parotid glands, oral cavity, larynx, mandible, and tem-
poromandibular joints.
Treatment design and delivery
The plans were designed and optimized using the Pinnacle
inverse planning system. The prescribed radiation dose
was 69.76 Gy at 2.18 Gy per fraction delivered to the
PTVnx and PTVnd, and 60.8 Gy at 1.9 Gy per fraction de-
livered to the PTV1. The PTV2 was treated to 54.4 Gy at
1.7 Gy per fractions. All patients were treated once daily,
five fractions weekly. Dose constrains to the critical struc-
tures were within the tolerance according to the RTOG
0225 protocol, and efforts were made to meet the criteria
as closely as possible. IMRT was delivered via seven fixed-
gantry angles with an Elekta Synergy Linear Accelerator
(Elekta Ltd.) with step-and-shoot treatment techniques.
Acquiring and processing CT data during IMRT
Repeat CT scans were acquired for each patient with the
same mask and isocenter as the initial simulation CT
scan after each five fractions and at the end of the full
treatment course using a 24-slice CT scanner (Somatom
Sensation Open, Siemens Medical Solutions, Erlangen,
Germany). The datasets were denoted as CT-1, CT-2,
CT-3, CT-4, CT-5, and CT-6, respectively. Each new CT
dataset was registered with the initial planning CT data-
set through VoxAlign Deformation Engine provided by
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ning contours on the new CT was conducted and man-
ual modification was performed if needed. Changes in
the volume of GTVnx, GTVnd, and parotid and shift of
the parotid centroid were calculated by comparing the
new CT and the planning CT.
A hybrid IMRT plan was generated by superimposing
the initial treatment plan (Plan-0) to each repeated new
CT image. After recalculation of the dose distribution
on the new CT images, the dose delivered by the hybrid
plans to the redelineated target volumes and OARs were
recorded and analyzed (adaptive replanning was not
suitable for CT-6 since the CT-6 images were acquired
at the end of IMRT. There were only 5 hybrid plans,













III 13 68.4Statistical analysis
The Kolmogorov-Smirnov test was used to test data for
normality. Mean ± standard deviation was used for data
with normal distribution; whereas median (interquartile
range) was used for data with skewed distribution. A paired
sample T-test or Wilcoxon rank-sum test was chosen
based on the data types. The correlation between weight
loss and parameters associated with anatomic changes was
estimated using Pearson’s correlation. Analysis of variance
(ANOVA) was performed to determine significant dosi-
metric changes at any time point (trigger point) of the en-
tire treatment course. A probability value less than 0.05
was considered significant. Analyses were performed using




Platinum-based chemo 17 89.5Results
Patient characteristics
Between August 2012 and December 2013, a total of 19
patients diagnosed with undifferentiated non-keratinizing
NPC were enrolled into this study. There were 11 men
and 8 women with median age of 46 years (range, 22–70).
Stage distributions according to the 2010 AJCC Staging
System were as follows: stages II, 3 patients; stage III, 13
patients; and stage IV, 3 patients. Concurrent platinum-
based chemotherapy was given to 17 patients, and no
chemotherapy to 2 patients. The characteristics of the pa-
tient cohort are listed in Table 1.Changes in volume of GTVnx and GTVnd
Steady volume reduction in GTVnx and GTVnd was ob-
served over time. Compared with the baseline, the vol-
umes of GTVnx and GTVnd at the end of IMRT were
decreased significantly by 65.6 ± 13.3 % and 72.7 ± 13.3 %
(p = 0.001 and 0.046), corresponding to a reduction rate of
17.3 ± 10.4 %/week and 22.2 ± 15.0 %/week, respectively.Changes in volume and displacement of the parotid
At the treatment completion, the volume of the left parotid
decreased by 38.0 ± 15.3 %, corresponding to a reduction
rate of 7.9 ± 9.6 %/week; whereas for the right parotid, the
volume reduction was 39.2 ± 14.7 %, corresponding to a re-
duction rate of 7.8 ± 11.3 %/week. The most significant vol-
ume reduction occurred at the third week, with its value of
15.8 ± 6.8 % (p = 0.016) and 14.4 ± 7.6 % (p = 0.003) for the
left and right parotids, respectively.
The displacements of the centroid for the left parotid
were −0.27 ± 0.25 cm, 0.04 ± 0.12 cm, and 0.14 ± 0.20 cm
in the right-left (RL), anterior-posterior (AP), and
superior-inferior (SI) directions, respectively. Significant
shifts were noticed in the RL and AP directions (p = 0.001
and 0.018). While for the right parotid, the displacements
of its centroid were 0.31 ± 0.19 cm, 0.01 ± 0.21 cm, and
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ively. Significant shift occurred in the AP direction
(p < 0.001). The centroid displacement for the pa-
rotids is illustrated in Fig. 1.Weight loss during the treatment course
Gradual weight loss was observed during the course of
IMRT, with an average loss of 1.5 ± 2.2 %/week. Com-
pared with the baseline, the percentages of weight loss
after the 1st, 2nd, 3rd, 4th, and 5th weeks and at the
completion of treatment were 1.7 ± 1.5 % (p < 0.001),
2.5 ± 1.9 % (p < 0.001), 3.9 ± 2.2 % (p < 0.001), 4.8 ±
2.8 % (p < 0.001), 6.2 ± 3.3 % (p < 0.001), and 8.3 ± 5.1 %
(p < 0.001), respectively.
Weight loss correlated significantly with reductions in
the volume of parotids and their centroid shift towards
the medial direction. No correlation was observed be-
tween the weight loss and the volumetric changes of
GTVnx and GTVnd (Table 2).Dosimetric changes in the target volumes
There was no significant difference in each homogeneity
index (HI) for all the targets between the original plan and
the hybrid plan. Some parameters for PTVnx and PTV1
improved significantly as treatment continued, notably
starting from the 10th fraction. These parameters included
mean dose (Dmean), dose to 95 % of the volume (D95),
percentage of the volume receiving 95 % of the prescrip-
tion dose (V95), and conformity index (CI) for PTVnx,
and Dmean, D95, and CI for PTV1. Other parameters in-
cluding percentage of the volume receiving >110 % of the
prescription dose (V110) for PTVnx, and V95 and V110
for PTV1 changed less or not significantly. The dosimetric
parameters for PTVnd remained the same in general ex-
cept for D95 which had significant improvement at the
15th and 25th fraction, and for V95 which had significant
improvement starting from the 10th fraction to 25th frac-
tion; whereas for PTV2, a similar trend of dosimetric
changes was also observed (Table 3).Fig. 1 Centroid displacements of the parotid glands. Centroid displacemen
AP, and SI directions throughout the entire treatment course. Lt=left, Post =Dosimetric changes in OARs
Dmean for the brain stem and spinal cord increased sig-
nificantly over the IMRT course, occurring as early as at
the 15th and 5th fractions, respectively. Dmean and V30
for the left and right parotids increased significantly, be-
ginning at the fifteenth and twentieth fraction, respect-
ively. For the glottis, right eye, and left lens, significant
increase in Dmax or Dmean was found in some time
point (s) during the treatment. Table 4 illustrates the dosi-
metric changes in some OARs. No significant differences
were found in dosimetric parameters between the initial
treatment plan and the hybrid plan in other OARs includ-
ing the temporal lobes, optic nerves, optic chiasm, left eye,
right lens, cochleae, mandible, temporomandibular joints,
esophagus, oral cavity, supraglottis, and subglottis (not
shown in Table 4).
Timing of adaptive treatment replanning
It is reasonable to postulate that any anatomic changes
during the treatment course may not certainly result in
marked dosimetric changes. So ART may not be neces-
sary for a patient who has no significant dosimetric
changes at some time point even if statistical anatomic
changes exist at the same time. Based on this concept,
we considered a trigger point at which significant dosi-
metric variation for a specific parameter was present as
an indicator for ART replanning. First of all, dosimetric
parameters in Plan-0 were compared with those in the
following hybrid plans separately until statistical differ-
ences were found. For example, if significant difference
was found in the target dose coverage or overdose to the
OARs between Plan-0 and Plan-1, adaptive replanning
would be initiated after the 5th fraction (here the 5th
fraction was considered a trigger point). Then parame-
ters in Plan-1 were compared with those in the follow-
ing hybrid plans until another trigger point was found,
and so on. In this way, the trigger points for each
selected parameter throughout the treatment course
could be identified. Table 5 illustrates the suggested
trigger points at which adaptive replanning would bets of the left (left part) and right parotid gland (right part) in the RL,
posterior, Sup = superior, Rt = right, Ant = anterior, Inf = inferior
Table 2 Correlation between weight loss and anatomic changes of the parotids and tumor
Anatomic change R2* P value
Volume reduction in PG-Lt 0.359 <0.001
Volume reduction in PG-Rt 0.294 <0.001
Weight loss Shift towards medial direction for PG-Lt centroid 0.325 <0.001
Shift towards medial direction for PG-Rt centroid 0.594 <0.001
Volume reduction in GTVnx 0.006 0.467
Volume reduction in GTVnd 0.0004 0.842
*Pearson correlation coefficient
PG-Lt left parotid gland, PG-Rt right parotid gland
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replans at the 5th and 15th fractions were proposed. This
was largely because most of the trigger points occurred at
these time points.
Discussion
Similar to other head-and-neck cancers, patients with
NPC disease also experience marked changes during
IMRT. These changes include shrinkage of the primary
disease and involved lymph nodes, weight loss, and geo-
metric/volumetric variations of the OARs. Fung et al.
[14] acquired daily megavoltage CT (MVCT) images and
registered them to the corresponding planning CT im-
ages for 30 NPC patients treated with helical tomother-
apy. At the end of treatment, there was a volume
reduction of 35.70 ± 20.06 % for the posterolateral wall
of nasopharynx (P-NP) which was a surrogate for the
primary disease, corresponding to a daily reduction of
0.99 ± 0.55 %. In a study by Cheng et al. [20], the mean
shrinkages of the nasopharyngeal disease and metastatic
lymph nodes were 9.1 and 16.2 % at 30 Gy, and 13.1 and
28.7 % at 50 Gy, respectively. Barker et al. [19] found that
the GTV for head-and-neck cancer treated with definitive
external beam RT decreased throughout the course of
fractionated RT, at a median rate of 0.2 cm3. On the last
day of treatment, the median volume loss of the initial
GTV was 69.5 % (range, 9.9–91.9 %). This was consistent
with our findings. In the present study, progressive
tumor regression for GTVnx and GTVnd was observed
over time. The volumes of GTVnx and GTVnd at the
end of IMRT were decreased significantly by 65.6 ±
13.3 % and 72.7 ± 13.3 % (p = 0.001 and 0.046), corre-
sponding to reduction rates of 17.3 ± 10.4 %/week and
22.2 ± 15.0 %/week, respectively.
Weight loss is a common event for head-and-neck
cancer patients when RT is given with or without con-
current chemotherapy. Ng et al. [21] found that at the
end of RT, 82 % of NPC patients had significant weight
loss and were in negative energy balance, which per-
sisted for more than 6 months. Although NPC patients
who received IMRT lost less weight than those who re-
ceived conventional RT, weight loss in patients treatedwith IMRT should not be underestimated. In a study by
Qiu et al. [22], weight loss of 5.81 ± 2.34 kg was ob-
served. Cheng et al. [20] found that most NPC patients
who were treated with IMRT experienced significant
weight loss during the RT course. Compared with the
baseline, mean weight loss at 30 and 50 Gy were 5.4 and
9.3 %, respectively. In the present study, we found an
average weight loss of 1.5 ± 2.2 % per week. Besides,
there was a significant weight loss at each time point
from the first week to the end of treatment course, indi-
cating that the patients experienced progressive weight
loss. Patients in our study lost less body weight than
those in Cheng’s study. This may be attributed to the
discrepancy in the patients’ baseline physical status, se-
verity of complications caused by treatment itself, and
support care between the two studies. Significant weight
loss during RT may have an negative impact on treat-
ment outcome, including lower quality-of-life (QOL)
scores, poorer treatment compliance, prolonged recovery
time and hospital stay, and poorer prognosis [23–26].
The parotids are the most frequently changed organs
in NPC patients throughout the treatment course, both
in the volume and in the displacement. Wang et al. [7]
showed a volume reduction of 14.7 % for the left parotid
and 18.2 % for the right parotid during IMRT for locally
advanced NPC by comparing the initial planning CT and
a repeat CT obtained after treatment at a dose of 40 Gy.
Lu et al. [16] found a volume reduction of 35.1 ± 20.0 %
and 24.6 ± 11.9 % for the left and right parotids, respect-
ively, after 25 fractions. Similar reduction trends for the
parotid could also be reflected by another study in which
the mean percentage volume loss was 47.54 ± 14.27 % at
the treatment completion, and the mean loss rate was
estimated to be 1.35 ± 0.39 %/day. In addition, the mean
center of mass (COM) of the parotid shifted progres-
sively towards the medial and superior aspects during
treatment. Also the mean medial and superior displace-
ment for both sides of the parotid were 0.34 ± 0.27 cm
and 0.24 ± 0.39 cm, respectively (both P < 0.001) [14]. In
our study, the volume of both sides of the parotid at the
treatment completion decreased significantly, comparing
with the baseline. We found that the most significant
Table 3 Dosimetric changes in different target volumes
Plan-0 Plan-1 Plan-2 Plan-3 Plan-4 Plan-5
PTVnx
Dmean (Gy) 71.17 ± 1.49 71.31 ± 1.44 71.41 ± 1.43 71.50 ± 1.40 71.60 ± 1.42 71.61 ± 1.44
P value 0.073 0.004 0.001 <0.001 0.001
D95 (Gy) 67.40 ± 2.48 67.54 ± 2.32 67.64 ± 2.25 67.86 ± 2.26 68.23 ± 2.04 68.18 ± 2.17
P value 0.404 0.256 0.040 0.004 0.015
V110 (%) 0.29 ± 0.65 0.30 ± 0.64 0.34 ± 0.75 0.29 ± 0.70 0.31 ± 0.86 0.32 ± 0.88
P value 0.447 0.102 0.990 0.887 0.852
V95 (%) 95.97 ± 5.06 96.29 ± 4.76 96.68 ± 4.4 97.21 ± 3.77 97.72 ± 3.59 97.48 ± 4.34
P value 0.158 0.032 0.013 0.005 0.027
HI 1.09 ± 0.03 1.09 ± 0.03 1.09 ± 0.03 1.09 ± 0.03 1.09 ± 0.03 1.09 ± 0.03
P value 0.244 0.244 0.116 0.258 0.678
CI 0.76 ± 0.24 0.77 ± 0.24 0.78 ± 0.23 0.80 ± 0.22 0.81 ± 0.22 0.82 ± 0.21
P value 0.141 0.044 0.005 0.004 0.004
PTVnd
Dmean (Gy) 71.60 ± .08 71.51 ± 1.08 71.56 ± 1.12 71.68 ± 1.08 71.73 ± 1.25 71.81 ± 1.22
P value 0.134 0.634 0.334 0.312 0.090
D95 (Gy) 66.43 ± 3.16 66.88 ± 3.31 66.89 ± 3.27 67.03 ± 3.27 67.27 ± 3.98 67.60 ± 3.57
P value 0.093 0.116 0.025 0.061 0.011
V110 (%) 0.74 ± 1.43 0.70 ± 1.29 0.71 ± 1.37 0.74 ± 1.45 0.8 ± 1.66 0.76 ± 1.65
P value 0.528 0.386 0.984 0.984 0.902
V95 (%) 95.09 ± 4.56 96.02 ± 4.21 96.02 ± 4.43 96.09 ± 4.47 96.66 ± 5.44 96.75 ± 5.85
P value 0.066 0.034 0.050 0.010 0.033
HI 1.10 ± 0.04 1.10 ± 0.04 1.10 ± 0.04 1.10 ± 0.04 1.10 ± 0.03 1.10 ± 0.03
P value 0.282 0.159 0.056 0.186 0.150
CI 0.80 ± 0.20 0.79 ± 0.18 0.80 ± 0.18 0.81 ± 0.18 0.82 ± 0.19 0.83 ± 0.18
P value 0.355 0.951 0.244 0.063 0.102
PTV1
Dmean (Gy) 68.06 ± 2.22 68.38 ± 2.03 68.52 ± 2.04 68.62 ± 1.96 68.69 ± 2.05 68.74 ± 2.06
P value 0.014 0.001 0.003 0.001 0.001
D95 (Gy) 60.00 ± 4.12 60.63 ± 3.91 61.04 ± 4.11 61.08 ± 4.33 61.24 ± 4.41 61.20 ± 4.43
P value 0.146 0.020 0.004 0.017 0.009
V95 (%) 95.58 ± 4.23 96.80 ± 2.97 96.90 ± 3.17 96.69 ± 3.73 96.79 ± 3.59 96.93 ± 3.46
P value 0.093 0.071 0.051 0.077 0.019
HI 1.25 ± 0.03 1.25 ± 0.03 1.25 ± 0.03 1.25 ± 0.03 1.25 ± 0.03 1.25 ± 0.03
P value 0.478 0.706 0.258 0.053 0.086
CI 0.90 ± 0.07 0.92 ± 0.05 0.93 ± 0.06 0.93 ± 0.05 0.93 ± 0.06 0.93 ± 0.06
P value 0.040 0.038 0.006 0.046 0.008
PTV2
Dmean (Gy) 60.21 ± 6.65 59.98 ± 6.73 60.07 ± 6.90 60.10 ± 6.80 60.08 ± 6.94 60.20 ± 6.64
P value 0.071 0.345 0.412 0.379 0.940
D95 (Gy) 47.47 ± 6.42 46.73 ± 6.12 46.94 ± 6.18 46.89 ± 6.21 46.75 ± 16.1 46.61 ± 6.06
P value 0.008 0.069 0.038 0.020 0.023
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Table 3 Dosimetric changes in different target volumes (Continued)
V95 (%) 92.48 ± 0.97 91.39 ± 1.10 91.74 ± 1.12 91.84 ± 0.92 91.56 ± 1.25 91.52 ± 0.52
P value 0.015 0.071 0.088 0.028 0.057
HI 1.42 ± 0.05 1.42 ± 0.05 1.42 ± 0.05 1.42 ± 0.05 1.42 ± 0.05 1.42 ± 0.05
P value 0.334 0.229 0.167 0.173 0.130
CI 0.87 ± 0.13 0.86 ± 0.13 0.86 ± 0.13 0.86 ± 0.13 0.86 ± 0.13 0.86 ± 0.13
P value 0.032 0.184 0.271 0.082 0.173
Difference was calculated by comparing Plan-0 and each hybrid plan
Dmean mean dose, D95 dose to 95 % of the volume, V110 percentage of the volume receiving more than 110 % of the prescription dose, V95 percentage of the
volume receiving 95 % of the prescription dose, HI homogeneity index, CI conformity index
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volumetric variation, the displacement of the centroid
for the parotids also changed. Significant shifts were
found in the AP direction for the right parotid, and in
the RL and AP directions for the left parotid.
It has been reported that shrinkage of the parotid and
shift of its centroid are correlated with weight loss.
Barker et al. [19] found that in head-and-neck cancer,
the medial shift in parotid COM correlated highly with
weight loss during fractionated RT course. Similar find-
ings were also shown in our study. Weight loss signifi-
cantly correlated with the shrinkage of parotids and
their centroid shift towards the medial direction, but no
correlation was observed between the weight loss and
the volumetric changes of GTVnx and GTVnd. The pa-
rotids may be exposed to a high dose region due to theirTable 4 Dosimetric changes in OARs
OARs Parameter Plan-0 Plan-1
BT Dmax (Gy) 53.21 ± 3.51 53.48 ± 4.59
P value 0.613
SC Dmax (Gy) 40.74 ± 3.22 41.34 ± 3.36
P value 0.017
PG-Lt Dmean (Gy) 34.31 ± 5.53 34.33 ± 5.58
P value 0.990
V30 (%) 47.08 ± 2.06 47.57 ± 2.95
P value 0.773
PG-Rt Dmean (Gy) 32.98 ± 3.58 33.31 ± 4.88
P value 0.673
V30 (%) 43.72 ± 6.49 44.79 ± 9.94
P value 0.499
Glottis Dmean (Gy) 40.97 ± 7.27 41.42 ± 7.67
P value 0.167
Eye-Rt Dmax (Gy) 27.55 ± 8.34 30.30 ± 8.33
P value 0.057
Lens-Lt Dmax (Gy) 6.87 ± 1.50 8.35 ± 3.40
P value 0.046
OARs organs at risk, BT brain stem, SC spinal cord, PG-Lt left parotid gland, PG-Rt rigmedial shift or volume reduction during the IMRT
course. Significant weight loss may be used as a surro-
gate for a large medial parotid shift or larger parotid vol-
ume loss, implying that modified replanning may be
needed to avoid excessive irradiation to the parotid.
Significant anatomic changes during the treatment
course in NPC patients may affect the dose distribution.
The initial plan based on pretreatment CT images that
are only snapshots of the patient’s anatomy at a static
time point do not precisely reflect the actual dose distri-
bution during fractionated IMRT. Fung et al. [13] cre-
ated two new adaptive plans (PII-ART and PIII-ART)
for 10 NPC patients undergoing Hi-Art Tomotherapy
based on up-to-date CT images and contours and used
these plans for treatment in phase two (PII; after 25th
fraction) and phase three (PIII; after 35th fraction),Plan-2 Plan-3 Plan-4 Plan-5
53.51 ± 3.87 55.19 ± 3.40 55.84 ± 3.12 56.54 ± 3.72
0.590 <0.001 <0.001 <0.001
43.08 ± 6.27 42.84 ± 5.72 42.66 ± 4.88 42.24 ± 3.87
0.041 0.030 0.012 0.001
35.23 ± 6.07 36.72 ± 6.67 37.17 ± 7.47 37.40 ± 7.62
0.421 0.031 0.027 0.020
50.35 ± 5.00 52.38 ± 3.93 51.33 ± 4.05 53.37 ± 4.72
0.229 0.017 0.063 0.010
33.44 ± 4.61 34.69 ± 5.02 35.40 ± 3.93 38.58 ± 1.07
0.533 0.083 0.003 0.038
45.19 ± 9.16 48.34 ± 0.86 50.10 ± 8.51 51.61 ± 0.05
0.298 0.051 0.002 0.001
41.51 ± 7.60 41.72 ± 7.46 41.45 ± 7.46 42.61 ± 9.69
0.062 0.035 0.100 0.137
28.48 ± 8.30 30.20 ± 8.88 30.14 ± 9.45 29.79 ± 0.25
0.321 0.014 0.016 0.090
8.04 ± 3.01 8.41 ± 3.27 8.56 ± 2.83 8.60 ± 3.91
0.035 0.041 0.008 0.082
ht parotid gland, Eye-Rt right eye, Lens-Lt left lens
Table 5 Suggested trigger points for adaptive replanning
Parameter Week 1 Week 2 Week 3 Week 4 Week 5
PTV2 (D95/V95/CI) *
Brain stem (Dmax) * *






Sum 3 0 4 1 1
Note that parameters without statistically significant difference analyzed by
ANOVA were not shown in the table
*Significant difference at a trigger point, indicating necessity of replanning
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NART) were generated using the original contours
pasted on the PII- and PIII-CT sets by CT-CT fusion.
Dosimetric comparisons were made between the NART
plans and the corresponding ART plans. They found
that without replanning, the doses to D95 for all the tar-
get volumes were increased with better dose uniformity,
whereas the OARs received higher doses compared with
the corresponding ART plans. The total dose to D1 for
the brain stem and spinal cord significantly increased
by 7.87 ± 7.26 and 10.69 ± 6.72 %, respectively. There
were also significantly increased maximum doses to the
optic chiasm and pituitary gland, and significantly in-
creased mean doses to both sides of the parotid. Cheng
et al. [20] performed CT and MRI scans at 30 Gy and
50 Gy intervals for 19 NPC patients treated with IMRT.
When comparing the initial plan with the hybrid plans
which were generated by superimposing the initial plan to
the repeat CT images, they found that the hybrid plans
demonstrated significantly higher dose to most of target
volumes with greater dose inhomogeneity, higher max-
imum doses to the spinal cord and brainstem, and higher
median doses to the parotid. Wang et al. [7] noticed that
after IMRT at the 40 Gy dose point, dose coverage of all
the targets remained unchanged, whereas the dose deliv-
ered to the parotid glands and spinal cord increased signifi-
cantly. The results were in line with ours in this study.
Findings mentioned above indicated that although the ac-
tually delivered doses to the targets may be higher or at
least not worse than the planned ones, doses to OARs, par-
ticularly the parotids, spinal cord, and brain stem, however,
significantly increased.
Determining an appropriate time point at which ART is
intervened in a timely manner is critical to ensure that the
planned dose to the targets and OARs can be delivered
faithfully throughout the entire IMRT course. Workflow
for ART includes re-simulating, re-contouring, and treat-
ment re-designing, which is a time-consuming and heavy
workload process. Thus daily ART is not always applicable
in many cancer centers. Many reports in recent years sug-
gested that mid-to-late phase of the treatment course was
appropriate timing for ART. Lu et al. [16] recommended
that ART should be initiated after 25 fractions of IMRT to
ensure adaptive doses to the targets and critical normal tis-
sues. Cheng et al. [20] showed that doses to some OARs
such as the brain stem, spinal cord and parotids were sig-
nificantly increased at 30 Gy during the course of IMRT,
while the target coverage remained adequate. So replan-
ning was suggested at this time point. In another study by
Fung et al., significant anatomic changes were found at
the 9th, 19th, and 29th fractions. The authors thus recom-
mended ART replanning at these three time points. Con-
trary to Fung’s study, we selected parameters only related
with dose distributions as the endpoint to determinewhether a replan was needed. As explained in the previous
section, significant anatomic changes may not certainly re-
sult in remarkable changes in dosimetric effects. So only
dosimetric changes were chosen as determinant for ART
replanning in this study. Bearing this concept in mind, we
identified the trigger points at which ART replanning
would be initiated. However, for practical consideration,
two replans at the 5th and 15th fractions were proposed.
This was largely because most of the trigger points oc-
curred at these time points, as shown in Table 5.
It should be noted that all patients in the present study
were treated with the original plan. The repeat CT scans
during IMRT were only used for research, and no ART
replanning was prepared for patient treatment. Whether
ART replanning can transfer into dosimetric or clinical
benefits remains unknown. To answer these questions, a
further study is underway to investigate the impact of
ART on dosimetric parameters and clinical outcomes.Conclusions
In summary, there were significant anatomic and dosimet-
ric changes in the targets and OARs during the course of
IMRT. Weight loss significantly correlated with the shrink-
age of parotids and their centroid shift towards the medial
direction. The target dose coverage in the hybrid plans did
not get worse, comparing with the original plan, but over-
dose occurred in some critical structures. Significant dosi-
metric changes should be considered as a trigger point at
which ART replanning would be initiated. Based on the
dosimetric analysis, D95/V95/CI for PTV2, Dmax for the
brain stem, spinal cord, right eyeball and left lens, and
Dmean/V30 for the parotids and glottis were taken into ac-
count for predicting the need for ART. Two replans at the
5th and 15th fractions were suggested for performing ART.Competing interests
The authors declare that they have no competing interests.
Huang et al. Radiation Oncology  (2015) 10:192 Page 9 of 9Authors’ contributions
HL designed the study. HH gathered the data and performed the analysis.
WD, MY, and WY designed the treatment planning and recalculated the
dose on new CT images. The manuscript was written by LH, all other authors
helped and finally approved the final manuscript.
Acknowledgements
This work was supported by Health and Family Planning Commission of
Guangxi Zhuang Autonomous Region (Z2014201 and Z2013370) and
National Natural Science Foundation of China (81160284). The authors thank
their colleagues for their participations in the acquisition of the CT images
and data processing.
Author details
1Departments of Radiation Oncology, People’s Hospital of Guangxi Zhuang
Autonomous Region, Nanning, China. 2Department of Medical Oncology,
People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Received: 24 March 2015 Accepted: 3 September 2015
References
1. Lu H, Yao M. The current status of intensity-modulated radiation therapy in the
treatment of nasopharyngeal carcinoma. Cancer Treat Rev. 2008;34:27–36.
2. Fang FM, Chien CY, Tsai WL, Chen HC, Hsu HC, Lui CC. Quality of life and
survival outcome for patients with nasopharyngeal carcinoma receiving
three-dimensional conformal radiotherapy vs. intensity-modulated
radiotherapy-a longitudinal study. Int J Radiat Oncol Biol Phys.
2008;72:356–64.
3. Fang FM, Tsai WL, Chen HC, Hus HC, Hsiung CY, Chien CY, et al. Intensity-
modulated or conformal radiotherapy improves the quality of life of
patients with nasopharyngeal carcinoma: comparisons of four radiotherapy
techniques. Cancer. 2007;109:313–21.
4. Marucci L, Marzi S, Sperduti I, Giovinazzo G, Pinnarò P, Benassi M, et al.
Influence of intensity-modulated radiation therapy technique on xerostomia
and related quality of life in patients treated with intensity-modulated
radiation therapy for nasopharyngeal cancer. Head Neck. 2012;34:328–35.
5. Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, et al.
Xerostomia and quality of life after intensity-modulated radiotherapy vs.
conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial
report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys.
2006;66:981–91.
6. Pow EH, Kwong DL, Sham JS, Lee VH, Ng SC. Can intensity-modulated
radiotherapy preserve oral health-related quality of life of nasopharyngeal
carcinoma patients? Int J Radiat Oncol Biol Phys. 2012;83:e213–21.
7. Wang RH, Zhang SX, Zhou LH, Zhang GQ, Yu H, Lin XD, et al. Volume and
dosimetric variations during two-phase adaptive intensity-modulated
radiotherapy for locally advanced nasopharyngeal carcinoma. Biomed Mater
Eng. 2014;24:1217–25.
8. Marzi S, Pinnarò P, D’Alessio D, Strigari L, Bruzzaniti V, Giordano C, et al.
Anatomical and dose changes of gross tumour volume and parotid glands for
head and neck cancer patients during intensity-modulated radiotherapy: effect
on the probability of xerostomia incidence. Clin Oncol. 2012;24:e54–62.
9. Chambers MS, Garden AS, Kies MS, Martin JW. Radiation-induced xerostomia
in patients with head and neck cancer: pathogenesis, impact on quality of
life, and management. Head Neck. 2004;26:796–807.
10. Chen WC, Lai CH, Lee TF, Hung CH, Liu KC, Tsai MF, et al. Scintigraphic
assessment of salivary function after intensity-modulated radiotherapy for
head and neck cancer: correlations with parotid dose and quality of life.
Oral Oncol. 2013;49:42–8.
11. Lee CC, Ho CY. Post-treatment late complications of nasopharyngeal
carcinoma. Eur Arch Otorhinolaryngol. 2012;269:2401–9.
12. McMillan AS, Pow EH, Kwong DL, Wong MC, Sham JS, Leung LH, et al.
Preservation of quality of life after intensity-modulated radiotherapy for
early-stage nasopharyngeal carcinoma: results of a prospective longitudinal
study. Head Neck. 2006;28:712–22.
13. Fung WW, Wu VW, Teo PM. Dosimetric evaluation of a three-phase adaptive
radiotherapy for nasopharyngeal carcinoma using helical tomotherapy. Med
Dosim. 2012;37:92–7.
14. Fung WW, Wu VW, Teo PM. Developing an adaptive radiation therapy
strategy for nasopharyngeal carcinoma. J Radiat Res. 2014;55:293–304.15. Wang X, Lu J, Xiong X, Zhu G, Ying H, He S, et al. Anatomic and dosimetric
changes during the treatment course of intensity-modulated radiotherapy
for locally advanced nasopharyngeal carcinoma. Med Dosim. 2010;35:151–7.
16. Lu J, Ma Y, Chen J, Wang L, Zhang G, Zhao M, et al. Assessment of
anatomical and dosimetric changes by a deformable registration method
during the course of intensity-modulated radiotherapy for nasopharyngeal
carcinoma. J Radiat Res. 2014;55:97–104.
17. Wang W, Yang H, Hu W, Shan G, Ding W, Yu C, et al. Clinical study of the
necessity of replanning before the 25th fraction during the course of
intensity-modulated radiotherapy for patients with nasopharyngeal
carcinoma. Int J Radiat Oncol Biol Phys. 2010;77:617–21.
18. Hansen EK, Bucci MK, Quivey JM, Weinberg V, Xia P. Repeat CT imaging and
replanning during the course of IMRT for head-and-neck cancer. Int J Radiat
Oncol Biol Phys. 2006;64:355–62.
19. Barker JL, Garden AS, Ang KK, O’Daniel JC, Wang H, Court LE, et al.
Quantification of volumetric and geometric changes occurring during
fractionated radiotherapy for head-and-neck cancer using an integrated CT/
linear accelerator system. Int J Radiat Oncol Biol Phys. 2004;59:960–70.
20. Cheng HC, Wu VW, Ngan RK, Tang KW, Chan CC, Wong KH, et al. A
prospective study on volumetric and dosimetric changes during intensity-
modulated radiotherapy for nasopharyngeal carcinoma patients. Radiother
Oncol. 2012;104:317–23.
21. Ng K, Leung SF, Johnson PJ, Woo J. Nutritional consequences of
radiotherapy in nasopharynx cancer patients. Nutr Cancer. 2004;49:156–61.
22. Qiu C, Yang N, Tian G, Liu H. Weight loss during radiotherapy for
nasopharyngeal carcinoma: a prospective study from Northern China. Nutr
Cancer. 2011;63:873–9.
23. Nourissat A, Vasson MP, Merrouche Y, Bouteloup C, Goutte M, Mille D, et al.
Relationship between nutritional status and quality of life in patients with
cancer. Eur J Cancer. 2008;44:1238–42.
24. Shahmoradi N, Kandiah M, Peng LS. Impact of nutritional status on the
quality of life of advanced cancer patients in hospice home care. Asian Pac
J Cancer Prev. 2009;10:1003–9.
25. Mantsopoulos K, Koch M, Zenk J, Iro H. The value of percutaneous
endoscopic gastrostomy in ENT tumor patients. HNO. 2010;58:333–40.
26. Munshi A, Pandey MB, Durga T, Pandey KC, Bahadur S, Mohanti BK. Weight
loss during radiotherapy for head and neck malignancies: what factors
impact it? Nutr Cancer. 2003;47:136–40.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
